Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in liquid biopsy for monitoring the disease status of cancer patients. Resulting from tumor cell apoptosis, ctDNA can be used to monitor different cancers by targeting cancer-specific mutations. With Ph.D. level scientists and extensive experience in Immune Biomarker Discovery for Immune Monitoring, Creative Biolabs offers accurate and effective solutions for the analysis of ctDNA in the liquid biopsy to help our clients' biomarker development project.
ctDNA is single- or double-stranded DNA released by the tumor cells into the blood, harboring the mutations of the original tumor. ctDNA is a small fraction of the total cell-free (cfDNA) that contains point mutations, rearrangements, amplification, and even gene copy number variations. Previous studies have shown that ctDNA carries genetic information from the entire tumor genome, providing insights into clonal heterogeneity and evolution of all solid cancers present at any one time. Since ctDNA provides detailed information via a minimally invasive 'liquid biopsy', eliminating the morbidity associated with the serial sampling of tumors for monitoring cancer patients, analysis of ctDNA can be tailored for different cancers by targeting specific mutations. Studies have indicated that ctDNA is a promising biomarker that can obtain quantitative and qualitative comprehensive tumor DNA in a minimally invasive manner. It can be potentially used in the early detection of cancer, assessing the risk of postoperative recurrence and monitoring the efficacy of therapy.
Fig.1 The potential origins of ctDNA and the hypothesis of genometastasis. (Cheng, 2016)
With the simultaneous ability to assess numerous genes and numerous tissues, liquid biopsy is suitable for comprehensive genomic profiling. To avoid the limitations of ctDNA liquid biopsies, including false negatives, false positives, low signal-to-noise ratio and short half-life of ctDNA extracted, Creative Biolabs has developed an efficient ctDNA extraction kit, which is designed for rapid extraction of ctDNA using paramagnetic particles. False positives and false negatives can be reduced by maximizing the recovery of 100 bp to 550 bp DNA fragments. With industry-leading expertise and state-of-the-art equipment, Creative Biolabs has pioneered the analysis of ctDNA for Biomarker Discovery.
Creative Biolabs has developed a range of nucleic acid assays to detect mutations in the following genes in breast cancer, lung cancer, and colon cancer.
NGS makes it possible to detect low levels of ctDNA in the bloodstream with sensitivity and specificity. In addition to detecting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA.
For more detailed information, please feel free to contact us for a detailed quote and further discussion with our scientists.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
